OFIX

SEC source: 0001209191-19-003953 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,601

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.76, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-064314 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,401

SEC source: 0001209191-18-057416 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,361

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017.

SEC source: 0001209191-18-057416 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,748

SEC source: 0001209191-18-057412 · doc4.xml · derivative · entry 6

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,700

Underlying: Common Stock · 4,300 shares

Expires 2024-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: These stock options vest in 25% increments on each of September 17, 2015, 2016, 2017 and 2018.

SEC source: 0001209191-18-057412 · doc4.xml · nonDerivative · entry 5

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,479

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $61.87, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-057412 · doc4.xml · nonDerivative · entry 4

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,179

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.51 to $61.39, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-057412 · doc4.xml · nonDerivative · entry 3

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-057412 · doc4.xml · nonDerivative · entry 2

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,479

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.61 to $61.87, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-057412 · doc4.xml · nonDerivative · entry 1

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,129

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.54 to $61.39, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-18-057410 · doc4.xml · derivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 7,000 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 26, 2016.

SEC source: 0001209191-18-057410 · doc4.xml · nonDerivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,740

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.16, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-18-057410 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-057399 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,311

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2018.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.81 to $61.87, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-057399 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,511

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.76 to $61.75, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-054970 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,368

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.10 to $56.04, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-054398 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,317

SEC source: 0001209191-18-052569 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,740

SEC source: 0001209191-18-050036 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,841

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.29, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-050360 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,290

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 5, 2018.

SEC source: 0001209191-18-049966 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,907

SEC source: 0001209191-18-046092 · doc4.xml · nonDerivative · entry 4

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,341

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.12 to $55.16, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.

SEC source: 0001209191-18-046092 · doc4.xml · nonDerivative · entry 3

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,641

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.63 to $54.43, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-046092 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,141

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.46 to $53.37, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-046092 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,541

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.14 to $51.79, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-042924 · doc4.xml · nonDerivative · entry 1

SICARD JOHN · CIK 0001734027 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,900

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042922 · doc4.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,167

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042919 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,429

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042916 · doc4.xml · nonDerivative · entry 1

MARKS LILLY · CIK 0001645735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,929

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042914 · doc4.xml · nonDerivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,966

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042912 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,197

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042910 · doc4.xml · nonDerivative · entry 1

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,629

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042908 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,887

F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019.

SEC source: 0001209191-18-042332 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,290

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.18 to $59.04, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-041678 · doc4.xml · derivative · entry 7

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,250 shares

Expires 2023-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · derivative · entry 6

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 5

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,992

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.27 to $57.45, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,142

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.27 to $57.25, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,992

F1 · kind: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 2, 2018.

SEC source: 0001209191-18-038962 · doc4.xml · derivative · entry 6

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,750 shares

Expires 2023-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

SEC source: 0001209191-18-038962 · doc4.xml · derivative · entry 5

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2023-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

SEC source: 0001209191-18-038962 · doc4.xml · nonDerivative · entry 4

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,859

F2 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.42 to $60.61, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-038962 · doc4.xml · nonDerivative · entry 3

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,055

F2 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.42 to $60.40, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-038962 · doc4.xml · nonDerivative · entry 2

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

SEC source: 0001209191-18-038962 · doc4.xml · nonDerivative · entry 1

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2018.

SEC source: 0001209191-18-038639 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,260

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0001209191-18-038641 · doc4.xml · derivative · entry 6

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2019-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

SEC source: 0001209191-18-038641 · doc4.xml · derivative · entry 5

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2018-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.